FSAP-mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE

European Journal of Immunology

Volumn 46, Issue 3, 2016, Pages 762-771

  Marsman, Gerben ^a,b   Stephan, Femke ^a,b   de Leeuw, Karina ^c   Bulder, Ingrid ^a,b   Ruinard, Jessica T ^a,b   de Jong, Jan ^a,b   Westra, Johanna ^c   Bultink, Irene E M ^d   Voskuyl, Alexandre E ^d   Aarden, Lucien A ^a,b   Luken, Brenda M ^a,b   Kallenberg, Cees G M ^c   Zeerleder, Sacha ^a,b,e  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Antinuclear antibodies; DAMPs; Factor VII activating protease; Nucleosomes; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; FACTOR VII ACTIVATING PROTEASE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; PROTEINASE; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; HABP2 PROTEIN, HUMAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NUCLEOSOME; SERINE PROTEINASE;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DISEASE ACTIVITY; DNA CONTENT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; JURKAT CELL LINE; MALE; NUCLEOSOME; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; CHEMISTRY; DEFICIENCY; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; SECRETION (PROCESS); SERUM; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; APOPTOSIS; AUTOANTIBODIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLAMMATION; JURKAT CELLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NUCLEOSOMES; SERINE ENDOPEPTIDASES; SERUM; YOUNG ADULT;

EID: 84959369237     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201546010     Document Type: Article

References (43)

1. Dörner, T., Jacobi, A. M., Lee, J. and Lipsky, P. E., Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J. Immunol. Methods 2011. 363: 187-197.
2. Kalaaji, M., Fenton, K. A., Mortensen, E. S., Olsen, R., Sturfelt, G., Alm, P. and Rekvig, O. P., Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int. 2007. 71: 664-672.
3. Yurasov, S., Wardemann, H., Hammersen, J., Tsuiji, M., Meffre, E., Pascual, V. and Nussenzweig, M. C., Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 2005. 201: 703-711.
4. Gaipl, U. S., Sheriff, A., Franz, S., Munoz, L. E., Voll, R. E., Kalden, J. R. and Herrmann, M., Inefficient clearance of dying cells and autoreactivity. Curr. Top. Microbiol. Immunol. 2006. 305: 161-176.
5. Muñoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A. and Herrmann, M., The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 2010. 6: 280-289.
6. Fehr, E.-M., Spoerl, S., Heyder, P., Herrmann, M., Bekeredjian-Ding, I., Blank, N., Lorenz, H.-M. et al., Apoptotic-cell-derived membrane vesicles induce an alternative maturation of human dendritic cells which is disturbed in SLE. J. Autoimmun. 2013. 40: 86-95.
7. Biermann, M. H. C., Veissi, S., Maueröder, C., Chaurio, R., Berens, C., Herrmann, M. and Munoz, L. E., The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets. Expert Rev. Clin. Immunol. 2014. 10: 1151-1164.
8. Detanico, T., Guo, W. and Wysocki, L. J., Predominant role for activation-induced cytidine deaminase in generating IgG anti-nucleosomal antibodies of murine SLE. J. Autoimmun. 2015. 58: 67-77.
9. Silva, M. T., Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett. 2010. 584: 4491-4499.
10. Vanden Berghe, T., Vanlangenakker, N., Parthoens, E., Deckers, W., Devos, M., Festjens, N., Guerin, C. J. et al., Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ. 2010. 17: 922-930.
11. Urbonaviciute, V., Fürnrohr, B. G., Meister, S., Munoz, L., Heyder, P., De Marchis, F., Bianchi, M. E. et al., Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 2008. 205: 3007-3018.
12. Christensen, S. R., Kashgarian, M., Alexopoulou, L., Flavell, R. A., Akira, S. and Shlomchik, M. J., Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 2005. 202: 321-331.
13. Wu, X. and Peng, S. L., Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 2006. 54: 336-342.
14. Christensen, S. R., Shupe, J., Nickerson, K., Kashgarian, M., Flavell, R. A. and Shlomchik, M. J., Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006. 25: 417-428.
15. Savarese, E., Steinberg, C., Pawar, R. D., Reindl, W., Akira, S., Anders, H.-J. and Krug, A., Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 2008. 58: 1107-1115.
16. Demaria, O., Pagni, P. P., Traub, S., de Gassart, A., Branzk, N., Murphy, A. J., Valenzuela, D. M. et al., TLR8 deficiency leads to autoimmunity in mice. J. Clin. Invest. 2010. 120: 3651-3662.
17. Summers, S. A., Hoi, A., Steinmetz, O. M., O'Sullivan, K. M., Ooi, J. D., Odobasic, D., Akira, S. et al., TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J. Autoimmun. 2010. 35: 291-298.
18. Urbonaviciute, V., Starke, C., Pirschel, W., Pohle, S., Frey, S., Daniel, C., Amann, K. et al., Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus. Arthritis Rheum. 2013. 65: 1612-1623.
19. Papadimitraki, E. D., Tzardi, M., Bertsias, G., Sotsiou, E. and Boumpas, D. T., Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. Lupus. 2009. 18: 831-835.
20. Chen, R., Kang, R., Fan, X.-G. and Tang, D., Release and activity of histone in diseases. Cell Death Dis. 2014; 5:e1370.
21. Li, T., Prokopec, S. D., Morrison, S., Lou, W., Reich, H., Gladman, D., Urowitz, M. et al., Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2015. 54: 449-457.
22. Amoura, Z., Piette, J. C., Chabre, H., Cacoub, P., Papo, T., Wechsler, B., Bach, J. F. et al., Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum. 1997. 40: 2217-2225.
23. Jørgensen, M. H., Rekvig, O. P., Jacobsen, R. S., Jacobsen, S. and Fenton, K. A., Circulating levels of chromatin fragments are inversely correlated with anti-dsDNA antibody levels in human and murine systemic lupus erythematosus. Immunol. Lett. 2011. 138: 179-186.
24. van der Vlag, J. and Berden, J. H. M., Lupus nephritis: role of antinucleosome autoantibodies. Semin. Nephrol. 2011. 31: 376-389.
25. Zeerleder, S., Zwart, B., te Velthuis, H., Manoe, R., Bulder, I., Rensink, I. and Aarden, L. A., A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells. FEBS Lett. 2007. 581: 5382-5388.
26. Stephan, F., Marsman, G., Bakker, L. M., Bulder, I., Stavenuiter, F., Aarden, L. A. and Zeerleder, S., Cooperation of factor VII-activating protease and serum DNase I in the release of nucleosomes from necrotic cells. Arthritis Rheumatol. (Hoboken, N.J.). 2014. 66: 686-693.
27. Liang, Y. Y., Arnold, T., Michlmayr, A., Rainprecht, D., Perticevic, B., Spittler, A. and Oehler, R., Serum-dependent processing of late apoptotic cells for enhanced efferocytosis. Cell Death Dis. 2014. 5: e1264.
28. Stephan, F., Hazelzet, J. A., Bulder, I., Boermeester, M. A., van Till, J. O., van der Poll, T., Wuillemin, W. A. et al., Activation of factor VII-activating protease in human inflammation: a sensor for cell death. Crit. Care. 2011. 15: R110.
29. Zeerleder, S., Zwart, B., te Velthuis, H., Stephan, F., Manoe, R., Rensink, I. and Aarden, L. A., Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP). FASEB J. 2008. 22: 4077-4084.
30. Etscheid, M., Hunfeld, A., König, H., Seitz, R. and Dodt, J., Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism. Biol. Chem. 2000. 381: 1223-1231.
31. Yamamichi, S., Fujiwara, Y., Kikuchi, T., Nishitani, M., Matsushita, Y. and Hasumi, K., Extracellular histone induces plasma hyaluronan-binding protein (factor VII activating protease) activation in vivo. Biochem. Biophys. Res. Commun. 2011. 409: 483-488.
32. Aarden, L. A., de Groot, E. R. and Feltkamp, T. E., Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann. N. Y. Acad. Sci. 1975. 254: 505-515.
33. van Nieuwenhuijze, A. E. M., van Lopik, T., Smeenk, R. J. T. and Aarden, L. A., Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus. Ann. Rheum. Dis. 2003. 62: 10-14.
34. Gauthier, V. J., Tyler, L. N. and Mannik, M., Blood clearance kinetics and liver uptake of mononucleosomes in mice. J. Immunol. 1996. 156: 1151-1156.
35. Licht, R., Dieker, J. W. C., Jacobs, C. W. M., Tax, W. J. M. and Berden, J. H. M., Decreased phagocytosis of apoptotic cells in diseased SLE mice. J. Autoimmun. 2004. 22: 139-145.
36. Decker, P., Wolburg, H. and Rammensee, H. G., Nucleosomes induce lymphocyte necrosis. Eur. J. Immunol. 2003. 33: 1978-1987.
37. Hakkim, A., Fürnrohr, B. G., Amann, K., Laube, B., Abed, U. A., Brinkmann, V., Herrmann, M. et al., Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U. S. A. 2010. 107: 9813-9818.
38. Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D. S., Weinrauch, Y. et al., Neutrophil extracellular traps kill bacteria. Science 2004. 303: 1532-1535.
39. Leffler, J., Martin, M., Gullstrand, B., Tydén, H., Lood, C., Truedsson, L., Bengtsson, A. A. et al., Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol. 2012. 188: 3522-3531.
40. Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D. and Chang, C. H., Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992. 35: 630-640.
41. Roemisch, J., Feussner, A., Nerlich, C., Stoehr, H. and Weimer, T., The frequent Marburg I polymorphism impairs the pro-urokinase activating potency of the factor VII activating protease (FSAP). Blood Coagul. Fibrinolysis. 2002. 13: 433-441.
42. Meilof, J. F., Van der Lelij, A., Rokeach, L. A., Hoch, S. O. and Smeenk, R. J., Autoimmunity and filariasis. Autoantibodies against cytoplasmic cellular proteins in sera of patients with onchocerciasis. J. Immunol. 1993. 151: 5800-5809.
43. Souwer, Y., Griekspoor, A., Jorritsma, T., de Wit, J., Janssen, H., Neefjes, J. and van Ham, S. M., B cell receptor-mediated internalization of salmonella: a novel pathway for autonomous B cell activation and antibody production. J. Immunol. 2009. 182: 7473-7481.